Manoli Vourvahis
Overview
Explore the profile of Manoli Vourvahis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varma M, Vourvahis M
Clin Pharmacol Ther
. 2025 Jan;
PMID: 39807775
Rifampicin is a widely employed index inhibitor to assess the impact of organic anion transporting polypeptide 1B (OATP1B) inhibition on investigational drugs. The observation of nitrosamines in certain drug products,...
2.
Hughes J, Amin N, Wojciechowski J, Vourvahis M
CPT Pharmacometrics Syst Pharmacol
. 2024 Nov;
14(2):317-330.
PMID: 39564924
Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis describe a collection of liver conditions characterized by the accumulation of liver fat. Despite biopsy being the reference standard for determining the severity...
3.
Kadar E, Holliman C, Vourvahis M, Rodrigues A
Bioanalysis
. 2024 Feb;
16(6):347-362.
PMID: 38376139
It has become common practice to assess solute carrier transporter (SLC)-mediated drug-drug interactions (DDIs) by quantitating various individual endogenous compounds as biomarkers in human plasma and urine. The goal of...
4.
Qiu R, Fonseca K, Bergman A, Lin J, Tess D, Newman L, et al.
Clin Transl Sci
. 2023 Dec;
17(1):e13644.
PMID: 38108609
PF-06835919, a ketohexokinase inhibitor, presented as an inducer of cytochrome P450 3A4 (CYP3A4) in vitro (human primary hepatocytes), and static mechanistic modeling exercises predicted significant induction in vivo (oral midazolam...
5.
Huh Y, Plotka A, Wei H, Kaplan J, Raha N, Towner J, et al.
Pharm Res
. 2023 Aug;
40(11):2639-2651.
PMID: 37561322
Purpose: Ritlecitinib, an inhibitor of Janus kinase 3 and tyrosine kinase expressed in hepatocellular carcinoma family kinases, is in development for inflammatory diseases. This study assessed the impact of ritlecitinib...
6.
Wang X, Purohit V, Dowty M, Rodrigues D, Luo L, Mathialagan S, et al.
J Clin Pharmacol
. 2023 Feb;
63(7):784-797.
PMID: 36807251
Ritlecitinib, an inhibitor of Janus kinase 3 and hepatocellular carcinoma family kinases, is in development as potential treatment for several inflammatory diseases. In vitro studies presented ritlecitinib as an inhibitor...
7.
Lin J, Kimoto E, Yamazaki S, Vourvahis M, Bergman A, Rodrigues A, et al.
Clin Pharmacol Ther
. 2022 Dec;
113(5):1058-1069.
PMID: 36524426
Hepatic impairment (HI) is known to modulate drug disposition and may lead to elevated plasma exposure. The aim of this study was to quantitate the in vivo OATP1B-mediated hepatic uptake...
8.
Franzese R, Riccobene T, Carrothers T, Vourvahis M, Winter E, Lovern M, et al.
Clin Pharmacol Ther
. 2022 Oct;
113(1):182-195.
PMID: 36239478
Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor combination developed to treat serious Gram-negative bacterial infections; approved indications include complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired pneumonia including ventilator-associated pneumonia...
9.
Luo L, Vourvahis M, Horlbogen L, Patel R, Mathialagan S, Holliman C, et al.
Bioanalysis
. 2022 Sep;
14(14):971-984.
PMID: 36066071
Novel urinary biomarker evaluation approaches to support inhibition assessment for renal transporters (e.g., OCT2, multidrug and toxin extrusion proteins [MATEs]). Highly sensitive and robust hydrophilic interaction chromatography-MS/high-resolution MS assays, for...
10.
Liyanage M, Nikanjam M, McFadyen L, Vourvahis M, Rogg L, Moye J, et al.
Pediatr Infect Dis J
. 2022 Aug;
41(11):885-890.
PMID: 35980827
Background: Treatment and prophylaxis options for neonatal HIV are limited. This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing...